As numerous cancer treatments aim at reducing Akt–mTOR activity in the tumour, we wondered if this systemic reduction in Akt–mTORC1 signalling could have adverse effects on skeletal muscle during cancer cachexia, possibly by reducing mTORC1 signalling even further. This evidence concerns the gene AKT1 and neoplasm.